A new study shows that VEGF-driven retinal neovascularization depends on a VEGFR2-VEGFR3-ATF6-GRP78 signaling axis that ...
An experimental study reports that SP1-induced PDRG1 promotes the proliferation and metastasis of hepatocellular carcinoma by activating the Wnt/Ī²-catenin pathway and serves as an independent ...
The study met its key secondary endpoint of progression-free survival. In the ITT population, ivonescimab significantly prolonged PFS compared with durvalumab, with a median PFS of 8.4 months versus 5 ...
Pumitamig plus docetaxel demonstrated a confirmed objective response rate of 36.7% in patients with non-small cell lung ...
ROSETTA Lung-107 shows pumitamig plus docetaxel achieved 36.7% ORR and 6.9-month PFS after chemoimmunotherapy in metastatic NSCLC.
Pumitamig plus docetaxel demonstrated encouraging responses in squamous and non-squamous non-small cell lung cancer across PD-L1 expression levels with a confirmed objective response rate of ...
The vote went against FDA scientists who presented research on the six peptides, concluding there wasn't enough evidence to ...
Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results